GlobeNewswire·Jul 28, 2026, 6:30 AM ET

Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs

European Commission granted orphan medicinal product designation for [²¹²Pb]VMT-α-NET to treat gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Designation follows a positive opinion from the Committee for Orphan Medicinal Products of the European Medicines Agency
Incentives for the designation include protocol assistance, fee reductions, & up to 10 years of market exclusivity if approved
Perspective Therapeutics is evaluating [²¹²Pb]VMT-α-NET in an ongoing Phase 1/2a study for SSTR2-positive neuroendocrine tumors
Interim clinical data presented at the 2026 ASCO Annual Meeting support the drug's potential to provide significant benefit over approved therapies
The radiopharmaceutical targets SSTR2 receptors & delivers the alpha-emitting isotope lead-212 to tumor sites
Clinical trial NCT05636618 focuses on patients with unresectable or metastatic SSTR2-positive tumors who have not received prior radiopharmaceutical therapies
Efficacy results for half of Cohort 2 patients & both Cohort 1 patients have been reported, with additional data pending for other cohorts
Perspective Therapeutics is advancing a portfolio including VMT-α-NET for neuroendocrine tumors, VMT01 for melanoma, & PSV359 for solid tumors